Evropská unie - slovinština - EMA (European Medicines Agency)

retrophin europe ltd - holinska kislina - presnova, urojene napake - terapija z jetri in jeter - cholic kisline fgk je primerna za zdravljenje prirojeno napake primarnih žolčnih kislin sintezo, pri otrocih od enega meseca starosti za stalno vseživljenjsko zdravljenje do odrasle dobe, ki zajema naslednje en encim napake:sterol 27-hydroxylase (predstavitev, kot cerebrotendinous xanthomatosis, ctx) pomanjkljivosti;2- (ali alfa-) methylacyl-coa racemase (amacr) pomanjkljivosti;holesterola 7 alfa-hydroxylase (cyp7a1) pomanjkanje.

Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

msd vaccins - virus ošpic (sev enders’ edmonston), živ, oslabljen, virus rdečk (sev wistar ra 27/3), živ, oslabljen, virus varicella (sev oka/merck), virus mumpsa (sev jeryl lynn (nivo b)), živ, oslabljen - prašek in vehikel za suspenzijo za injiciranje - virus ošpic (sev enders’ edmonston), živ, oslabljen 1000 ccid50 / 1 viala; virus rdečk (sev wistar ra 27/3), živ, oslabljen 10000 ccid50 / 1 viala; virus varicella (sev oka/merck) 1000 ccid50 / 1 viala; virus mumpsa (sev jeryl lynn (nivo b)), živ, oslabljen 10000 ccid50 / 1 viala - mešano cepivo proti ošpicam, mumpsu, rdečkam in noricam z oslabljenimi virusi

Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - brivudin - tableta - brivudin 125 mg / 1 tableta - brivudin

Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - brivudin - tableta - brivudin 125 mg / 1 tableta - brivudin

Evropská unie - slovinština - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristal - kontracepcija, postcoital - spolni hormoni in zdravila genitalni sistem, nujne kontracepcije - nujna kontracepcija v 120 urah (pet dni) nezaščitenega spolnega odnosa ali odpovedi kontracepcije.

Evropská unie - slovinština - EMA (European Medicines Agency)

accord healthcare s.l.u. - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - navedeno kot eno bolezen spreminjanje terapije v zelo aktivna recidivno nakazila multiplo sklerozo, za naslednje skupine odraslih bolnikov in pediatričnih bolnikih, starih 10 let in več:bolniki z zelo aktivna bolezen kljub popolno in ustrezno tečaj zdravljenja z vsaj eno bolezen spreminjanje therapyorpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.

Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod

Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod

Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod

Evropská unie - slovinština - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.